Adhera Drug Patent Portfolio

Adhera owns 1 orange book drug protected by 2 US patents Given below is the list of Adhera's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7846961 α crystalline form of the arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it 05 Oct, 2029
Active
US6696481 Salt of perindopril and pharmaceutical compositions containing it 15 Apr, 2023 Expired


Given below is the list of recent legal activities going on the following drug patents of Adhera.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 23 May, 2022 US7846961
Payment of Maintenance Fee, 8th Year, Large Entity 17 Apr, 2018 US7846961
Post Issue Communication - Certificate of Correction 11 Apr, 2011 US7846961
Patent Issue Date Used in PTA Calculation 07 Dec, 2010 US7846961
Recordation of Patent Grant Mailed 07 Dec, 2010 US7846961
Issue Notification Mailed 17 Nov, 2010 US7846961
Dispatch to FDC 11 Nov, 2010 US7846961
Application Is Considered Ready for Issue 02 Nov, 2010 US7846961
Issue Fee Payment Received 21 Oct, 2010 US7846961
Issue Fee Payment Verified 21 Oct, 2010 US7846961
Mail Notice of Allowance 27 Sep, 2010 US7846961
Mail Examiner's Amendment 27 Sep, 2010 US7846961
Case Docketed to Examiner in GAU 24 Sep, 2010 US7846961
Notice of Allowance Data Verification Completed 24 Sep, 2010 US7846961
Date Forwarded to Examiner 13 Jul, 2010 US7846961


Adhera Drug Patents' Oppositions Filed in EPO

Adhera drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 13, 2005, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP03290383A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP07731039A Jan, 2017 Strawman Limited Revoked
EP07731039A Jan, 2017 LEK Pharmaceuticals d.d. Revoked
EP03290383A Apr, 2005 Teva Pharmaceutical Industries Ltd. Opposition rejected


Adhera's Family Patents

Adhera drugs have patent protection in a total of 41 countries. It's US patent count contributes only to 2.9% of its total global patent coverage. 11 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Adhera Drug List

Given below is the complete list of Adhera's drugs and the patents protecting them.


1. Prestalia

Prestalia is protected by 2 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7846961 α crystalline form of the arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it 05 Oct, 2029
(4 years from now)
Active
US6696481 Salt of perindopril and pharmaceutical compositions containing it 15 Apr, 2023
(1 year, 6 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prestalia's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List